[go: up one dir, main page]

CO2017012381A2 - Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue - Google Patents

Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue

Info

Publication number
CO2017012381A2
CO2017012381A2 CONC2017/0012381A CO2017012381A CO2017012381A2 CO 2017012381 A2 CO2017012381 A2 CO 2017012381A2 CO 2017012381 A CO2017012381 A CO 2017012381A CO 2017012381 A2 CO2017012381 A2 CO 2017012381A2
Authority
CO
Colombia
Prior art keywords
dengue viral
mono
compounds
inhibitors
viral replication
Prior art date
Application number
CONC2017/0012381A
Other languages
English (en)
Inventor
Pierre Jean-Marie Bernard Raboisson
Bart Rudolf Romanie Kesteleyn
Tim Hugo Maria Jonckers
Arnaud Didier M Marchand
Jean-François Bonfanti
Dorothée Alice Marie-Eve Bardiot
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of CO2017012381A2 publication Critical patent/CO2017012381A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos de indol mono o disustituidos, a métodos para prevenir o tratar infecciones virales por dengue usando dichos compuestos y también se refiere a dichos compuestos para su uso como un medicamento, más preferiblemente para su uso como una medicina para tratar o prevenir infecciones virales por dengue. La presente invención se refiere adicionalmente a composiciones farmacéuticas o preparaciones de combinación de los compuestos, a las composiciones o preparaciones para su uso como un medicamento, más preferiblemente para la prevención o tratamiento de infecciones virales por dengue. La invención también se refiere a procesos para la preparación de los compuestos.
CONC2017/0012381A 2015-05-08 2017-11-30 Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue CO2017012381A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15166900 2015-05-08
EP16163342 2016-03-31
PCT/EP2016/059975 WO2016180696A1 (en) 2015-05-08 2016-05-04 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
CO2017012381A2 true CO2017012381A2 (es) 2018-03-28

Family

ID=56026812

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0012381A CO2017012381A2 (es) 2015-05-08 2017-11-30 Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue

Country Status (39)

Country Link
US (5) US10696632B2 (es)
EP (2) EP3896072B1 (es)
JP (4) JP6752821B2 (es)
KR (2) KR102610491B1 (es)
CN (3) CN113045476B (es)
AU (2) AU2016259677B2 (es)
BR (1) BR112017023904A2 (es)
CA (1) CA2981845C (es)
CL (1) CL2017002817A1 (es)
CO (1) CO2017012381A2 (es)
CR (2) CR20200152A (es)
CY (1) CY1124548T1 (es)
DK (1) DK3294738T3 (es)
EA (1) EA034978B1 (es)
EC (2) ECSP17073878A (es)
ES (2) ES2941674T3 (es)
GT (1) GT201700234A (es)
HR (1) HRP20210675T1 (es)
HU (1) HUE054724T2 (es)
IL (2) IL255430B (es)
JO (2) JOP20160086B1 (es)
LT (1) LT3294738T (es)
MD (1) MD3294738T2 (es)
MX (2) MX383932B (es)
MY (1) MY198339A (es)
NI (1) NI201700137A (es)
PE (2) PE20221579A1 (es)
PH (1) PH12017502000B1 (es)
PL (1) PL3294738T3 (es)
RS (1) RS62029B1 (es)
SG (1) SG10201900315SA (es)
SI (1) SI3294738T1 (es)
SM (1) SMT202100367T1 (es)
SV (1) SV2017005557A (es)
TW (2) TWI725969B (es)
UA (2) UA128183C2 (es)
UY (2) UY39706A (es)
WO (1) WO2016180696A1 (es)
ZA (2) ZA201707524B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
HRP20190139T1 (hr) * 2014-10-01 2019-03-22 Janssen Pharmaceuticals, Inc. Mono- ili di-supstituirani indoli kao inhibitori replikacije denga virusa
TWI681951B (zh) * 2014-10-01 2020-01-11 美商健生醫藥公司 作為登革熱病毒複製抑制劑之單-或二-取代的吲哚衍生物
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
HUE054936T2 (hu) 2016-03-31 2021-10-28 Janssen Pharmaceuticals Inc Helyettesített indol-származékok mint a dengue-vírus replikációjának inhibitorai
MX2018011788A (es) 2016-03-31 2019-05-20 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
AU2017240076A1 (en) 2016-04-01 2018-08-09 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN110753682B (zh) 2017-05-22 2023-06-30 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
ES2929667T3 (es) * 2017-05-22 2022-11-30 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
WO2021094563A1 (en) 2019-11-15 2021-05-20 Janssen Pharmaceuticals, Inc Treatment and prevention of dengue disease
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
WO2022094817A1 (en) 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Pharmaceutical formulation
CN113024440B (zh) * 2021-03-17 2023-05-16 凯莱英医药集团(天津)股份有限公司 连续化合成取代吲哚-2-羧酸的方法
CN117616010A (zh) 2021-06-29 2024-02-27 杨森制药公司 制备(s)-2-(4-氯-2-甲氧基苯基)-2-((3-甲氧基-5-(甲磺酰基)苯基)氨基)-1-(1h-吲哚-3-基)乙烯酮衍生物的方法
JP2025517683A (ja) 2022-05-12 2025-06-10 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウイルス感染症の治療及び/又は予防
CN115521307B (zh) * 2022-09-30 2023-09-22 甘肃皓天医药科技有限责任公司 一种5-卤代-7-氮杂吲哚的制备方法
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease
CN119306651B (zh) * 2024-10-11 2025-12-05 山东大学 一种吲哚3-酰胺类衍生物及其制备方法与应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69830335T2 (de) 1997-10-27 2006-02-02 Eli Lilly And Co., Indianapolis MORPHOLINO-N-ETHYL ESTER PRODROGEN VON INDOL sPLA 2 HEMMER
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
JP2005520795A (ja) 2001-12-12 2005-07-14 コンフォーマ・セラピューティクス・コーポレイション Hsp90阻害活性を有するプリン類似体
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
EP1844042A1 (en) 2005-01-14 2007-10-17 Genelabs Technologies, Inc. Indole derivatives for treating viral infections
KR20070102741A (ko) 2005-02-09 2007-10-19 미게닉스 인코포레이티드 플라비비리대 감염증을 치료하거나 예방하기 위한 조성물및 방법
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
AP2010005480A0 (en) 2008-06-03 2010-12-31 Siga Technologies Inc Small molecule inhibitors for the treatment or prevention of denque virus infection.
AU2009283195A1 (en) * 2008-08-18 2010-02-25 Yale University MIF modulators
JP5559174B2 (ja) 2008-08-19 2014-07-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 冷感−メントール受容体拮抗剤
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
AU2011205797B2 (en) 2010-01-15 2015-07-16 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
EP3060547B1 (en) 2013-10-23 2017-10-11 Janssen Sciences Ireland UC Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN106132962B (zh) 2014-01-31 2018-09-07 百时美施贵宝公司 作为凝血因子xia抑制剂的具有芳族p2’基团的大环化合物
HUE042277T2 (hu) 2014-06-04 2019-06-28 Amgen Inc Eljárások fehérjék begyûjtésére emlõssejttenyészetekbõl
US10208286B2 (en) 2014-06-04 2019-02-19 Fred Hutchinson Cancer Research Center Expansion and engraftment of stem cells using Notch 1 and/or Notch 2 agonists
NO2721243T3 (es) 2014-10-01 2018-10-20
HRP20190139T1 (hr) * 2014-10-01 2019-03-22 Janssen Pharmaceuticals, Inc. Mono- ili di-supstituirani indoli kao inhibitori replikacije denga virusa
TWI681951B (zh) 2014-10-01 2020-01-11 美商健生醫藥公司 作為登革熱病毒複製抑制劑之單-或二-取代的吲哚衍生物
ES2896198T3 (es) 2014-10-10 2022-02-24 Univ Rutgers Cebadores y sondas de reacción en cadena de polimerasa para Mycobacterium tuberculosis
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN108349880B (zh) 2015-07-22 2021-03-09 奥迈科斯治疗公司 用于治疗心脏疾病的cyp类花生酸代谢稳健类似物
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AU2016350868B2 (en) 2015-11-03 2022-03-31 Zoetis Services Llc Sol-gel polymer composites and uses thereof
EP3436444B1 (en) 2016-03-31 2020-05-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
MX2018011788A (es) 2016-03-31 2019-05-20 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
HUE054936T2 (hu) 2016-03-31 2021-10-28 Janssen Pharmaceuticals Inc Helyettesített indol-származékok mint a dengue-vírus replikációjának inhibitorai
CN109641956A (zh) 2016-04-01 2019-04-16 美国安进公司 Flt3的嵌合受体及其使用方法
PL3436030T3 (pl) 2016-04-01 2022-12-19 Kite Pharma, Inc. Receptory chimeryczne i sposoby ich zastosowania
BR112018068851B1 (pt) 2016-04-01 2022-11-22 Basf Se Composto de fórmula i, composição, métodos de combate ou controle de pragas invertebradas e de proteção de plantas, semente revestida e uso de pelo menos um composto
CA3018986A1 (en) 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CA3019149A1 (en) 2016-04-01 2017-10-05 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AU2017240076A1 (en) 2016-04-01 2018-08-09 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
WO2018167952A1 (ja) 2017-03-17 2018-09-20 三菱電機株式会社 アダプティブアレーアンテナ装置
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN110753682B (zh) 2017-05-22 2023-06-30 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
ES2929667T3 (es) 2017-05-22 2022-11-30 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue

Also Published As

Publication number Publication date
AU2020273314A1 (en) 2020-12-17
MX391754B (es) 2025-03-21
AU2020273314B2 (en) 2021-10-21
JOP20160086B1 (ar) 2021-08-17
CR20170490A (es) 2018-03-08
GT201700234A (es) 2018-11-26
US10696632B2 (en) 2020-06-30
MX2020011156A (es) 2022-04-21
EP3896072A1 (en) 2021-10-20
RS62029B1 (sr) 2021-07-30
JP2018515495A (ja) 2018-06-14
CN107873022A (zh) 2018-04-03
CR20200152A (es) 2020-09-08
PL3294738T3 (pl) 2021-12-13
NZ736934A (en) 2023-11-24
HK1252496A1 (zh) 2019-05-31
MX2017014293A (es) 2018-08-09
JOP20210109A1 (ar) 2023-01-30
JP2020125316A (ja) 2020-08-20
EA034978B1 (ru) 2020-04-14
IL272814B (en) 2021-02-28
PE20180232A1 (es) 2018-01-31
BR112017023904A2 (pt) 2018-07-17
UY36674A (es) 2016-11-30
MX383932B (es) 2025-03-14
JP6898493B2 (ja) 2021-07-07
JP7132399B2 (ja) 2022-09-06
UA128183C2 (uk) 2024-05-01
PE20221579A1 (es) 2022-10-06
CN107873022B (zh) 2021-03-12
CL2017002817A1 (es) 2018-05-11
PH12017502000A1 (en) 2018-03-26
JP2022166289A (ja) 2022-11-01
HK1252446A1 (zh) 2019-05-24
ZA201707524B (en) 2024-06-26
ZA202002435B (en) 2023-03-29
IL255430B (en) 2020-03-31
MD3294738T2 (ro) 2021-08-31
US11827602B2 (en) 2023-11-28
TWI744963B (zh) 2021-11-01
CN113045476A (zh) 2021-06-29
EA201792429A1 (ru) 2018-02-28
NZ765879A (en) 2024-09-27
ES2941674T3 (es) 2023-05-24
PH12017502000B1 (en) 2018-03-26
SI3294738T1 (sl) 2021-08-31
US10919854B2 (en) 2021-02-16
US20240182414A1 (en) 2024-06-06
IL255430A0 (en) 2017-12-31
HUE054724T2 (hu) 2021-09-28
CA2981845C (en) 2022-03-08
TWI725969B (zh) 2021-05-01
LT3294738T (lt) 2021-08-25
WO2016180696A1 (en) 2016-11-17
SG10201900315SA (en) 2019-02-27
ECSP17073878A (es) 2018-02-28
JP2021138752A (ja) 2021-09-16
AU2016259677A1 (en) 2017-10-26
SMT202100367T1 (it) 2021-07-12
JP6752821B2 (ja) 2020-09-09
EP3294738B1 (en) 2021-04-07
US20180346419A1 (en) 2018-12-06
CA2981845A1 (en) 2016-11-17
KR20180002644A (ko) 2018-01-08
EP3896072B1 (en) 2022-11-16
CN111303000A (zh) 2020-06-19
ECSP22023220A (es) 2022-05-31
US12172959B2 (en) 2024-12-24
ES2877404T3 (es) 2021-11-16
AU2016259677B2 (en) 2020-10-01
NI201700137A (es) 2019-05-07
TW201704208A (zh) 2017-02-01
TW202041499A (zh) 2020-11-16
HRP20210675T1 (hr) 2021-06-25
CN113045476B (zh) 2024-07-16
EP3294738A1 (en) 2018-03-21
KR102610493B1 (ko) 2023-12-05
KR102610491B1 (ko) 2023-12-06
CY1124548T1 (el) 2022-07-22
UY39706A (es) 2022-05-31
CN111303000B (zh) 2023-11-28
MY198339A (en) 2023-08-27
SV2017005557A (es) 2018-06-26
US20210171462A1 (en) 2021-06-10
JP7451626B2 (ja) 2024-03-18
KR20210048578A (ko) 2021-05-03
US20250230127A1 (en) 2025-07-17
UA121332C2 (uk) 2020-05-12
IL272814A (en) 2020-04-30
US20200270209A1 (en) 2020-08-27
DK3294738T3 (da) 2021-06-28

Similar Documents

Publication Publication Date Title
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
CO2018003471A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
CO2018003369A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP18073245A (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
ECSP18073264A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
JOP20180025A1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
CR20190447A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
MX2019013878A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MX2019013893A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
UY36339A (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue